Replies to post #5574 on InVivo Therapeutics Holdings Corp (NVIVQ)

[TheHound]

the value of the company isn't defined by its share price.

[Giovinco]

So what ? I am paying only $4.35 and the technology clearly works

> The FDA has thrown the studies back at least a year.

[BioBull1]

DD, I agree with everything you've stated. I think too many individuals fell in love with this stock and have blinders on. Lots of negative (news) lately. I say (news) simply because the CEO does not even have the guts to PR this information. Shareholders are left search and finding hidden gems like the last Investor Presentation update.

[BioBull1]

Investors may once again face additional dilution unless something drastically changes. The company had 41M as of June 2016 at a burn rate of ~1.5M per month. At the end of the year, Invivo will have roughly 33M. If we are currently burning through one and half million dollars a month supporting just one trial (how?), I anticipate an increase if Cervical SCI and Chronic trials ever take off. Therefore, for calendar year 2017, I am assuming Invivo now burns 2.1M per month (potentially more) or a little over 25 million. If the HDE is not submitted until Q1 or 1H of 2018, Invivo will be running on fumes once again with less than 10M in the bank. This is not accounting for any further delays, ongoing or new lawsuits, additional hires, etc.